Celularity Inc (CELU) stock
CELUNasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.48−0.09 (-15.41%)
Close on Nov 18, 2026Market cap $15.68MP/E –Yield –
Celularity gross profit
Gross profit is revenue minus the direct cost of the goods and services sold.
Celularity's gross profit for the twelve months ending Jun 30, 2026 was $3.59M, down 85.4% year over year. For fiscal 2025 it was $6.48M, down 83.5% from the year before. The highest annual figure on record is $39.23M in fiscal 2024.
Annual gross profit
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.48M | -83.5% |
| FY2024 | Dec 31, 2024 | $39.23M | +480.8% |
| FY2023 | Dec 31, 2023 | $6.76M | – |
| FY2022 | Dec 31, 2022 | -$1.69M | -114.5% |
| FY2021 | Dec 31, 2021 | $11.68M | +25.0% |
| FY2020 | Dec 31, 2020 | $9.35M | – |
Quarterly gross profit
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $3.09M | +524.5% |
| Q1 FY2026 | Mar 31, 2026 | $2.39M | -69.6% |
| Q4 FY2025 | Dec 31, 2025 | -$3.27M | -130.3% |
| Q3 FY2025 | Sep 30, 2025 | $1.38M | -74.5% |
| Q2 FY2025 | Jun 30, 2025 | $494.00K | -95.1% |
| Q1 FY2025 | Mar 31, 2025 | $7.87M | -39.6% |
| Q4 FY2024 | Dec 31, 2024 | $10.79M | +331.0% |
| Q3 FY2024 | Sep 30, 2024 | $5.41M | +2841.8% |
| Q2 FY2024 | Jun 30, 2024 | $9.99M | +367.6% |
| Q1 FY2024 | Mar 31, 2024 | $13.04M | +575.0% |
| Q4 FY2023 | Dec 31, 2023 | $2.50M | – |
| Q3 FY2023 | Sep 30, 2023 | $184.00K | – |
| Q2 FY2023 | Jun 30, 2023 | $2.14M | +257.8% |
| Q1 FY2023 | Mar 31, 2023 | $1.93M | +1.2% |
| Q4 FY2022 | Dec 31, 2022 | -$1.12M | -670.4% |
| Q3 FY2022 | Sep 30, 2022 | -$3.08M | -137.0% |
| Q2 FY2022 | Jun 30, 2022 | $597.00K | -66.0% |
| Q1 FY2022 | Mar 31, 2022 | $1.91M | +34.6% |
| Q4 FY2021 | Dec 31, 2021 | $196.00K | -90.5% |
| Q3 FY2021 | Sep 30, 2021 | $8.31M | +257.9% |
| Q2 FY2021 | Jun 30, 2021 | $1.76M | – |
| Q1 FY2021 | Mar 31, 2021 | $1.42M | – |
| Q4 FY2020 | Dec 31, 2020 | $2.07M | – |
| Q3 FY2020 | Sep 30, 2020 | $2.32M | – |
See a number that looks wrong?